3,* * Based on 95,334 patients with or without type 2 diabetes (T2DM) who filed a prescription for GLP-1based treatment (tirzepatide, semaglutide, or liraglutide) between 2010 and 2023 for any indication
Clinical Laboratory News online
A 2014 study of 134 cavaliers with healthy hearts showed a LA/Ao range from 0.47 to 0.94.* This could mean that if the cut-off ratio between a normal-sized CKCS left atrium and an enlarged one is arbitrarily assumed to be 1.6, then cavaliers with acutal enlarged atriums but with LA/Ao ratios as low as 0.95 and as high as 1.59 would not be treated with pimobendan when they should be regarded as in Stage B2 and therefore should be prescribed the drug
A particular relationship was established with the NO-system, and the advantage of the BPC 157 over the corresponding standard agents (i.e., corticosteroids, sulfasalazine, H2 blockers, anticholinergics, and proton pump inhibitors) which showed only weak, if any, effect on these fistulas closing (Skorjanec et al., 2009
[DOI] [PMC free article] [PubMed] [Google Scholar] 103.Hu T., Zhang Z., Xu C
